NCT05284656Active, not recruitingPhase 3
Effect of Folic Acid and/or Pentoxifylline on Patients With Chronic Kidney Disease
The Potential Nephro-protective Effect of Folic Acid and/or Pentoxifylline on Patients With Chronic Kidney Disease
Source: ClinicalTrials.gov · Last updated 11 Jun 2025
Brief summary (registry, in English)
The aim of this study is to evaluate the effect of administration of folic acid and /or pentoxifylline on patients with chronic kidney disease (CKD).
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 16 Feb 2022
- Start date
- 8 Jan 2022
- Primary completion date
- 12 Jun 2026
- Lead sponsor
- Al-Azhar University
- Diseases
- Chronic kidney disease
- NCT number
- NCT05284656
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 80
- From 8 Jan 2022 to the primary completion date, 12 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who had received immunosuppressive therapy
Other illness
- Contraindication to use of PTF drug: history of PTF or theophylline allergy, history of severe retinal hemorrhage or recent cerebral hemorrhage
- Those with active infections or inflammatory diseases or HIV infection
- Those with chronic liver disease .
Other
- Pregnant women
- Current use of PTF
- Non-compliant patients
Who the study is looking for
- Patients who have chronic kidney disease(CKD) stages 3-5
- Aged between18 - 60 years old.
- Both sexes.
- Stable clinical condition defined as no hospitalizations or cardiovascular events within the 3 months before screening
- Stable renal function (baseline serum creatinine had to have not increased by 50% in the 3 months before screening)
- No changes in concomitant medication during the study.
- Patients who accept to participate in the study.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Al-Azhar University Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.